# A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

> **NCT01247194** · PHASE1 · COMPLETED · sponsor: **Presidio Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Chronic Genotype 1 Hepatitis C Virus Infection

## Interventions

- **DRUG:** PPI-461
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01247194
- **Lead sponsor:** Presidio Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01247194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01247194, "A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01247194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*